Search

1 Dec 2019: Circ Genom Precis Med. 2019;12:e002507. DOI: 10.1161/CIRCGEN.119.002507 September 2019 397. BACKGROUND: Pediatric cardiomyopathies are a clinically and genetically heterogeneous group of heart muscle disorders associated with high morbidity and

18 Apr 2006: levels, is that overexpression of exogenous Tsg101 se-. questers endogenous Tsg101 binding partners (Vps28. ... Tal, a Tsg101-spe-. cific E3 ubiquitin ligase, regulates receptor endocytosis and retrovirus.

16 May 2008: derived from a retrovirus. Syncytins function in cell–cell fusion during trophoblast formation. Immunoglobulin (Ig)-like

23 Nov 2004: Endogenous SNX1 was enriched on tubularmembranes in close vicinity to endosomal vacuoles (Fig-ure 3). ... These data establish a role for endogenous SNX1in the retrieval of the CI-MPR from early endosomes tothe TGN.

19 Jan 2017: endogenous proteins with recombinant variantsrevealed the functional roles for all of the factorsand interactions. ... C) Immunoblots (IB) for triage components of control or BAG6 complex-depleted RRL replenished with recombinant BAG6 sub-complexes used

22 Jul 2007: cells infected with retrovirus only. Expression of intrabody. causes a morphological change in HT-1080 with reorganised. ... mice. All mice subcutaneously injected with EJ cells infected. with retrovirus only or retrovirus expressing the mutant.

8 Aug 2014: microscopy (Fig 4A). (B) Cells with endogenous Scc1 or Scc3 (K20783) C-terminal. ... at the indicated time points and compared to levels made by endogenous tagged.

19 Jun 2006: J Cell Biol 129: 1509–1522. Morita E, Sundquist WI (2004) Retrovirus budding. ... Keywords: prions; retrovirus budding; exosome; endosomal transport;lysosome; multivesicular bodySubmitted 24 May 2006; accepted 31 May 2006.

17 Jan 2006: 5A,B). Furthermore,there was a clear enrichment of endogenous SNX2 on SNX1. ... Cells were then fixed and stained againstendogenous SNX1, endogenous SNX2 and endogenous mVps26.

3 May 2002: This might be caused bycompetition for clathrin binding between the injectedpeptide and the endogenous protein, therebypreventing endogenous AP180 and AP2 frompromoting clathrin assembly at the plasmamembrane.